Shahnaz Shahinfar

Children's Hospital of Philadelphia — United States

Medicine · Health Sciences

35h-index15.1kcitations58works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Blood Pressure and Hypertension Studies(40), Chronic Kidney Disease and Diabetes(34), Diabetes Treatment and Management(13), Dialysis and Renal Disease Management(10), Renin-Angiotensin System Studies(9)

Publications58 total

International consensus definitions of clinical trial outcomes for kidney failure: 2020
Kidney International·2020· 113 citedOpen Access
Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis
Pediatric Nephrology·2018· 12 citedOpen Access
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis
Pediatric Nephrology·2018· 35 cited
An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis
Pediatric Nephrology·2018· 17 citedOpen Access
A Randomized, Open-Label, Dose-Response Study of Losartan in Hypertensive Children
Clinical Journal of the American Society of Nephrology·2014· 27 citedOpen Access
Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy
Diabetes Care·2013· 39 citedOpen Access
Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome
Pediatric Nephrology·2012· 47 cited
Losartan and enalapril are comparable in reducing proteinuria in children
Kidney International·2012· 41 cited
Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database
American Journal of Kidney Diseases·2011· 204 cited
Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment
Hypertension·2011· 178 citedOpen Access
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
Kidney International·2011· 342 cited
Comparison of Different Measures of Urinary Protein Excretion for Prediction of Renal Events
Journal of the American Society of Nephrology·2010· 184 citedOpen Access
Randomized, Double-Blind, Controlled Study of Losartan in Children with Proteinuria
Clinical Journal of the American Society of Nephrology·2010· 56 citedOpen Access
Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study
Diabetes Care·2008· 17 citedOpen Access
ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With Nephropathy
Journal of the American Society of Nephrology·2008· 90 citedOpen Access
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy:Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
University of Groningen research database (University of Groningen / Centre for Information Technology)·2007
Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy
Journal of the American Society of Nephrology·2007· 299 cited
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies
Journal of Hypertension·2007· 26 cited
A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension
Pediatric Nephrology·2007· 31 cited
A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension
Clinical Therapeutics·2006· 13 cited
page 1 of 3Next →

Frequent Co-authors

Barry M. Brenner(27), Dick de Zeeuw(20), Mark E. Cooper(19), William F. Keane(17), Giuseppe Remuzzi(12), Zhongxin Zhang(9), Zhongxin Zhang(8), William E. Mitch(7), Steven Snapinn(7), Thomas G. Wells(7), Hans‐Henrik Parving(6), Hiddo J.L. Heerspink(6), Gilbert W. Gleim(6), Paulette A. Lyle(6), Tania Z. Dickson(6), Robert D. Toto(5), Wayne Shaw(5), Denise Ramjit(5), Janet B. McGill(4), Roger L. Simpson(4)